High prevalence of loss of Y chromosome in the spermatozoa of young cancer survivors

This study reveals that young cancer survivors exhibit a significantly higher prevalence of loss of Y chromosome in their sperm compared to controls, suggesting this genetic alteration serves as a valuable biomarker for genomic instability, reduced fertility, and disease predisposition.

The Gist

The Big Picture: A "Glitch" in the Genetic Code

Imagine your body is a massive library, and every cell in your body holds a copy of the same instruction manual (your DNA). For men, one specific page in that manual is the Y chromosome. It's the page that says, "Make a male."

Usually, this page is very stable. But sometimes, due to stress, aging, or damage, cells start losing this specific page. This is called Loss of Y (LOY).

Scientists have known for a long time that older men often lose this page in their blood cells. It's like a library where, over time, some books start losing a few pages. But this study asked a scary question: What if this "page loss" happens in the sperm of young men, especially those who have survived cancer?

The Study: Checking the "Seed" vs. the "Soil"

The researchers looked at three groups of men:

1. Childhood Cancer Survivors: Men who beat cancer when they were kids.
2. Testicular Cancer Survivors: Men who beat cancer in their reproductive organs.
3. Healthy Controls: Men with no cancer history.

They took two samples from each man:

• Blood: To check the "soil" (the body's general cells).
• Sperm: To check the "seed" (the cells that create the next generation).

The Surprising Findings

1. The "Seed" is More Damaged than the "Soil"
The researchers found something shocking. In young men (ages 18–53), the Y chromosome was missing from sperm much more often than it was missing from blood.

• Analogy: Imagine a factory that makes toys. The office workers (blood cells) are mostly fine, but the assembly line robots (sperm cells) are dropping the "Male" instruction manual at a rate 10 times higher than the office workers.
• The Stats: About 24% of healthy men had this glitch in their sperm. But for cancer survivors, that number jumped to over 40%.

2. Cancer Survivors Have More Glitches
Men who had survived cancer were significantly more likely to have sperm missing the Y chromosome compared to healthy men.

• The Takeaway: Surviving cancer seems to leave a "scar" on the genetic machinery that makes sperm, even if the man is young and feels healthy.

3. The Glitch is Unstable
In the testicular cancer group, the researchers checked the same men multiple times over a few years. They found that the amount of "glitchy" sperm went up and down.

• Analogy: It's like a flickering lightbulb. Sometimes the light is bright (healthy sperm), sometimes it's dim (lots of missing Y chromosomes), and it changes from day to day. This suggests the damage isn't a one-time event; it's an ongoing, dynamic struggle within the body.

4. The "Ripple Effect" (Other Damage)
The most important discovery was that when a man's sperm was missing the Y chromosome, it was also more likely to have other types of genetic damage on the other chromosomes (the "autosomes").

• Analogy: If you find a torn page in a book, you should check the rest of the book. The researchers found that when the Y chromosome was missing, the rest of the "instruction manual" was often crumpled, torn, or rewritten incorrectly too. This suggests a global breakdown in how the body repairs its DNA.

Why Does This Matter?

1. For the Children
If a father's sperm is missing the Y chromosome, he might have trouble having a baby boy. In fact, previous studies show that testicular cancer survivors have more daughters than sons. This study suggests that the "missing page" might be the reason why. Furthermore, if the sperm has other genetic damage (the "crumpled pages"), it could lead to health issues or birth defects in the children, even if the father was cured of cancer years ago.

2. For the Father's Future Health
Losing the Y chromosome in blood cells is a known warning sign that a man might get sick later in life (like heart disease or other cancers). This study suggests that if a young man's sperm has this problem, it might be an early warning signal that his whole body is struggling to keep its DNA stable.

The Bottom Line

This research opens a new door. It suggests that sperm isn't just a carrier of life; it's a canary in the coal mine.

If a young man's sperm shows signs of losing the Y chromosome, it might mean:

• He has a higher risk of developing other diseases later in life.
• His children might face higher risks of health issues.
• The damage from past cancer treatments (or the cancer itself) is still affecting his genetic code long after he is "cured."

In simple terms: The body's ability to copy its instructions is shaky in these men. By checking the sperm, doctors might be able to spot hidden genetic trouble early, protecting both the father's future health and the health of his future children.

Technical Summary

1. Problem Statement

Genomic instability (GI) is a known driver of cancer development and a mechanism for genetic alterations in somatic cells. While Loss of the Y chromosome (LOY) is a well-established hallmark of GI in hematopoietic cells (H-LOY) and is associated with aging, chronic disease, and cancer in men over 50, its presence in younger men and in the germline (spermatozoa) is under-researched.

• The Gap: It is unknown if cancer survivors (specifically childhood and testicular cancer) exhibit GI in their sperm, potentially transmitting genetic aberrations to offspring. Previous studies suggest children of male cancer survivors have higher risks of congenital malformations and malignancies, but the mechanistic link (GI in sperm) remains unproven.
• The Hypothesis: The authors hypothesize that LOY in spermatozoa (SPERM-LOY) is a marker of global genomic instability in young men, is more prevalent in cancer survivors than controls, and is associated with broader structural genomic aberrations on autosomes.

2. Methodology

The study utilized a multi-cohort design with rigorous genotyping and statistical modeling.

• Study Cohorts:

  • Childhood Cancer (CC) Survivors: 76 subjects (mean age at diagnosis ~8.8 years; mean age at sampling ~30.3 years).
  • Testicular Cancer (TC) Survivors: 113 subjects (mean age at diagnosis ~31.2 years; mean age at sampling ~33.8 years). Note: TC patients provided longitudinal semen samples (up to 6 per patient).
  • Controls (CTRL): 126 healthy, fertile, age-matched males.
  • Total Samples: 759 samples (paired blood and semen where available).

• Sample Processing & Genotyping:

  • DNA was extracted from blood and semen.
  • Samples were genotyped using the Illumina Infinium Global Screening Array (GSAMD-24v3).
  • Detection Algorithm: The MoChA (Mosaic Chromosomal Alterations) pipeline was used to detect LOY. The primary threshold was set at >1% cellular fraction of LOY cells. Sensitivity analyses were performed with thresholds ranging from 2% to 10%.

• Statistical Analysis:

  • Bayesian Mixed-Effects Logistic Regression: Used to compare LOY prevalence across cohorts (CC, TC, CTRL) and tissues (blood vs. sperm), adjusting for covariates (age, smoking, treatment history).
  • Autosomal Aberration Analysis: A manual curation pipeline identified Sperm-Specific Autosomal Chromosomal Alterations (SS-ACAs)—structural variants present in sperm but absent in paired blood.
  • Correlation Analysis: Mann-Whitney U tests compared SS-ACA burden (count and genomic length) between subjects with SPERM-LOY (≥1%) and those without (<1%).

3. Key Contributions

• First Large-Scale Germline LOY Study: This is the first study to systematically quantify LOY in the sperm of young cancer survivors (ages 18–53) compared to controls.
• Tissue Discrepancy: It establishes that LOY is significantly more prevalent in sperm than in blood for young men, suggesting sperm is a more sensitive tissue for detecting early genomic instability.
• Link to Structural Instability: The study provides evidence linking SPERM-LOY to a higher burden of sperm-specific structural autosomal aberrations, suggesting SPERM-LOY is a marker for broader germline genomic instability.
• Clinical Implications: It proposes SPERM-LOY as a potential biomarker for fertility issues, disease predisposition in offspring, and future cancer risk in the father.

4. Key Results

A. Prevalence of SPERM-LOY

• Cancer vs. Controls: SPERM-LOY (>1% threshold) was significantly higher in cancer survivors compared to controls.
  • CC vs. CTRL: Odds Ratio (OR) = 2.2 (95% HDI: 1.02–3.88).
  • TC vs. CTRL: OR = 2.4 (95% HDI: 1.23–4.04).
  • Combined Survivors vs. CTRL: OR = 2.25 (p = 0.0014).
• Prevalence Rates:
  • Controls: ~23.6% of sperm samples showed LOY.
  • TC Survivors: ~42.6%.
  • CC Survivors: ~40.8%.
• Blood vs. Sperm: LOY was approximately an order of magnitude more frequent in sperm than in blood across all cohorts.
  • CC: OR = 9.5 (Sperm vs. Blood).
  • TC: OR = 24.0 (Sperm vs. Blood).
  • CTRL: OR = 9.7 (Sperm vs. Blood).
• Age and Treatment: Unlike H-LOY in older men, SPERM-LOY in this young cohort (18–53) showed no significant correlation with age, smoking, or specific cancer treatments (chemo/radiotherapy).

B. Longitudinal Dynamics

• In TC patients with multiple samples, SPERM-LOY levels varied significantly within individuals over time (47% of patients with serial samples showed variation). This suggests a highly dynamic pattern of clonal expansion in the germline.

C. Association with Structural Genomic Aberrations (SS-ACAs)

• SS-ACA Burden: Subjects with SPERM-LOY (≥1%) had a significantly higher burden of sperm-specific autosomal chromosomal alterations compared to those without LOY.
  • Mean number of ACAs: 1.33 (LOY≥1%) vs. 0.33 (LOY<1%) (p = 2×10⁻¹¹).
  • Mean genomic length: 15.91 Mb (LOY≥1%) vs. 4.71 Mb (LOY<1%) (p = 9×10⁻¹¹).
• This correlation held true when analyzing cancer survivors and controls separately, supporting the hypothesis that SPERM-LOY is a marker for global germline genomic instability.

D. Fertility and Sex Ratio

• The study notes that fathers with high SPERM-LOY may have reduced fertility or a skewed sex ratio (fewer male offspring), as a 45,X (Turner syndrome) conceptus is non-viable in males. This aligns with previous observations of a higher proportion of female offspring born to testicular cancer survivors.

5. Significance and Conclusion

• Biomarker Potential: SPERM-LOY emerges as a clinically useful biomarker for identifying young men with elevated genomic instability, potentially predicting future cancer risk, age-related diseases, and reduced fertility.
• Transgenerational Risk: The association between SPERM-LOY and structural autosomal aberrations suggests that cancer survivors may transmit a "mutator phenotype" to their offspring, explaining the increased risk of congenital malformations and malignancies in the children of cancer survivors.
• Mechanistic Insight: The findings challenge the notion that pre-pubertal germ cells are immune to genomic damage from cancer treatments, as SPERM-LOY was elevated regardless of whether the cancer was diagnosed before or after puberty.
• Future Directions: The authors propose that SPERM-LOY could be a precursor to H-LOY later in life and call for large-scale studies to investigate the genetic predisposition (SNPs) to SPERM-LOY and its long-term health consequences.

Limitations: The study is a preprint (not yet peer-reviewed). The CC cohort had heterogeneous diagnoses. The mechanism of LOY (meiotic loss vs. X/Y imbalance) requires further investigation.